Integrated Diagnostics (OTCMKTS:IDGXF) and Illumina (NASDAQ:ILMN) Head-To-Head Comparison

Illumina (NASDAQ:ILMN) and Integrated Diagnostics (OTCMKTS:IDGXF) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations and institutional ownership.

Profitability

This table compares Illumina and Integrated Diagnostics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Illumina	18.36%	29.84%	12.17%
Integrated Diagnostics	N/A	N/A	N/A

Earnings & Valuation

This table compares Illumina and Integrated Diagnostics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Illumina	$4.49 billion	6.33	$850.00 million	$5.36	35.13
Integrated Diagnostics	N/A	N/A	N/A	N/A	N/A

Illumina has higher revenue and earnings than Integrated Diagnostics.

Insider & Institutional Ownership

89.4% of Illumina shares are owned by institutional investors. 2.9% of Illumina shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations and price targets for Illumina and Integrated Diagnostics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Illumina	2	6	8	1	2.47
Integrated Diagnostics	0	0	0	0	0.00

Illumina presently has a consensus target price of $188.40, suggesting a potential upside of 0.06%. Given Illumina’s stronger consensus rating and higher possible upside, research analysts clearly believe Illumina is more favorable than Integrated Diagnostics.

Summary

Illumina beats Integrated Diagnostics on 10 of the 10 factors compared between the two stocks.

About Illumina

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.

About Integrated Diagnostics

Integrated Diagnostics Holdings plc, a consumer healthcare company, provides various medical diagnostics services to patients. It offers approximately 3,000 diagnostic pathology tests, such as immunology, microbiology, haematology, endocrinology, clinical chemistry, molecular biology, parasitology, histopathology, and genetics. The company also provides radiology services, including positron emission tomography computed tomography (PET-CT), magnetic resonance imaging (MRI), computed tomography (CT), mammography, ultrasound, x-ray, electromyography (EMG), electroencephalography, electroencephalogram (EEG), and electrocardiogram (ECG), as well as operates cath lab facilities. It operates in Egypt, Sudan, Jordan, Nigeria, and the Kingdom of Saudi Arabia. The company was founded in 1979 and is headquartered in Saint Helier, Jersey.